Protagonist Therapeutics (PTGX) Return on Equity (2017 - 2025)
Historic Return on Equity for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to 0.07%.
- Protagonist Therapeutics' Return on Equity fell 2500.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year decrease of 2500.0%. This contributed to the annual value of 0.54% for FY2024, which is 8300.0% up from last year.
- Protagonist Therapeutics' Return on Equity amounted to 0.07% in Q3 2025, which was down 2500.0% from 0.08% recorded in Q2 2025.
- Protagonist Therapeutics' Return on Equity's 5-year high stood at 0.46% during Q4 2024, with a 5-year trough of 0.65% in Q1 2023.
- In the last 5 years, Protagonist Therapeutics' Return on Equity had a median value of 0.28% in 2021 and averaged 0.18%.
- Its Return on Equity has fluctuated over the past 5 years, first surged by 10100bps in 2024, then crashed by -2800bps in 2025.
- Quarter analysis of 5 years shows Protagonist Therapeutics' Return on Equity stood at 0.4% in 2021, then tumbled by -39bps to 0.55% in 2022, then skyrocketed by 55bps to 0.25% in 2023, then skyrocketed by 284bps to 0.46% in 2024, then tumbled by -85bps to 0.07% in 2025.
- Its Return on Equity stands at 0.07% for Q3 2025, versus 0.08% for Q2 2025 and 0.08% for Q1 2025.